Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Royalty Pharma plc    RPRX   GB00BMVP7Y09

ROYALTY PHARMA PLC

(RPRX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/13/2021 01/14/2021 01/15/2021 01/19/2021 01/20/2021 Date
49.97(c) 51.25(c) 51.95(c) 51.85(c) 50.76 Last
2 324 489 1 317 710 4 324 219 4 221 924 2 833 437 Volume
+1.07% +2.56% +1.37% -0.19% -2.10% Change
More quotes
Financials (USD)
Sales 2020 1 960 M - -
Net income 2020 1 510 M - -
Net Debt 2020 3 632 M - -
P/E ratio 2020 20,5x
Yield 2020 0,97%
Sales 2021 2 102 M - -
Net income 2021 1 651 M - -
Net Debt 2021 4 264 M - -
P/E ratio 2021 19,2x
Yield 2021 1,30%
Capitalization 20 125 M 20 125 M -
EV / Sales 2020 12,1x
EV / Sales 2021 11,6x
Nbr of Employees -
Free-Float 37,0%
More Financials
Company
Royalty Pharma plc is engaged in investing in late stage biopharmaceutical products. The Company invests in academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The Company’s portfolio of pharmaceutical investment includes investments in approximately 45 commercial products and four development-stage product candidates. 
More about the company
All news about ROYALTY PHARMA PLC
01/19Minerva Neurosciences to Sell Royalty Interest in Depressive Disorder Drug; S..
MT
01/19ROYALTY PHARMA : Acquires Royalty Interest in Seltorexant from Minerva Neuroscie..
PU
01/15ROYALTY PHARMA : Q4 2020 Pre-Quarterly Results Communication
PU
01/08ROYALTY PHARMA : Raises Dividend 13% to $0.17 per Share
MT
01/08Royalty Pharma Announces 13% Dividend Increase
GL
01/07Royalty Pharma to Present at the J.P. Morgan Healthcare Conference on January..
GL
2020Royalty Pharma Announces Charitable Gifts to Support COVID-19 Research at Lea..
GL
2020ROYALTY PHARMA : Donates $1,000,000 to Support Mount Sinai's Covid-19 Patient Ca..
PU
2020Royalty Pharma Announces Expansion of Leadership Team
GL
2020INSIDER TRENDS : Repros Therapeutics Insider Extends 90-Day Selling Trend
MT
2020ROYALTY PHARMA : and Pablo and Almudena Legorreta Support Development of Antibod..
PU
2020BioCryst to Receive $325 Million in Funding From Royalty Pharma, Athyrium Cap..
MT
2020Royalty Pharma Acquires Royalty Interest in ORLADEYO and BCX9930 From BioCrys..
GL
2020Royalty Pharma's Q3 Net Income Attributable to Controlling Interests Declines..
MT
2020Royalty Pharma Reports Third Quarter 2020 Results
GL
More news
News in other languages on ROYALTY PHARMA PLC
2020ROYALTY PHARMA PLC : Veröffentlichung des Quartalsergebnisses
2020ROYALTY PHARMA PLC : publication des résultats trimestriels
2020ROYALTY PHARMA PLC : publication des résultats semestriels
2020ROYALTY PHARMA PLC : Veröffentlichung des Halbjahresergebnisses
2020EN DIRECT DES MARCHES : Kering, Capgemini, Ipsen, Bic, Cafom, Biosynex, Qualc..
More news
Analyst Recommendations on ROYALTY PHARMA PLC
More recommendations
Chart ROYALTY PHARMA PLC
Duration : Period :
Royalty Pharma plc Technical Analysis Chart | RPRX | GB00BMVP7Y09 | MarketScreener
Technical analysis trends ROYALTY PHARMA PLC
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 51,88 $
Last Close Price 51,85 $
Spread / Highest target 8,00%
Spread / Average Target 0,05%
Spread / Lowest Target -9,35%
EPS Revisions
Managers and Directors
NameTitle
Pablo Gerardo Legorreta Chairman & Chief Executive Officer
Terrance Patrick Coyne Chief Financial Officer & Executive Vice President
James F. Reddoch Chief Scientific Officer
Errol B. de Souza Independent Director
William E. Ford Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ROYALTY PHARMA PLC3.60%20 125
JOHNSON & JOHNSON3.43%428 525
ROCHE HOLDING AG2.98%307 190
NOVARTIS AG2.24%218 823
MERCK & CO., INC.1.70%210 474
PFIZER INC.-0.22%204 160